MDGL
MADRIGAL PHARMACEUTICALS, INC.
Next earnings Aug 3, 2026 (before open) · consensus $-2.38 EPS, $357M rev
Last earnings +7.4% on 2026-05-06
$512.65
▼ -0.22%$512.65▲ +81.15%
over 1Y
L $277.64EODHDH $602.83
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.2%
1W-0.0%
1M-2.8%
3M+0.4%
YTD-13.7%
1Y+81.2%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 23 analysts
Buy
Rezdiffra's blockbuster MASH launch quadrupled revenue to $958M; single-drug risk but a clear path to profitability.
Revenue $958M · FY2025
Madrigal owns Rezdiffra, the first FDA-approved therapy for noncirrhotic MASH (F2-F3 fibrosis), and the commercial launch is going exceptionally well: revenue exploded 432.1% to $958M in FY2025 from $180M in FY2024, with the EU adding a conditional marketing authorization (CMA) granted in August 2025. This is a textbook early-stage blockbuster ramp in a large, previously untreated indication, and losses are narrowing — net loss improved 38.1% to -$288M and operating cash burn fell to -$190M as the launch scales toward operating leverage.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $180M | $958M |
| Gross profit | — | — | — | — | — |
| Operating income | -$242M | -$294M | -$380M | -$498M | -$300M |
| Net income | -$242M | -$295M | -$374M | -$466M | -$288M |
| Diluted EPS | -$14.63 | -$17.23 | -$19.99 | -$21.90 | -$12.85 |
| Net margin | — | — | — | -258.6% | -30.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$11.9B
EV / EBITDA—
EV / Sales12.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.5%
FCF yield-1.6%
Quality & risk
ROIC (est.)-25.2%
Free cash flow-$190M
Total debt$340M
Net cash-$141M
Altman Z-Score9.28 safe
Piotroski F-Score3/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+3.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-17
- 8-K Earnings results2026-05-06
- 10-Q Quarterly report2026-05-06
- 8-K Officer / director change2026-04-28
- DEF 14A Proxy statement2026-04-28
- 8-K Earnings results2026-02-19
- 10-K Annual report2026-02-19
- 8-K Material agreement2026-01-30
- 8-K Officer / director change2025-12-11
Recent filings
all on EDGAR ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗S-8Filing2026-06-17open ↗8-KPeriod ending 2026-06-162026-06-17open ↗4Period ending 2026-06-012026-06-01open ↗144Filing2026-06-01open ↗4Period ending 2026-05-222026-05-22open ↗144Filing2026-05-22open ↗
Frequently asked
- Is MADRIGAL PHARMACEUTICALS, INC. (MDGL) a buy?
- MDGL currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Rezdiffra's blockbuster MASH launch quadrupled revenue to $958M; single-drug risk but a clear path to profitability.
- What is MADRIGAL PHARMACEUTICALS, INC.'s quality score?
- MDGL scores 51.3921568627451/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001157601, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/21/2026, 8:47:33 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.